Nisaa Wulan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nisaa Wulan has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Nick Scott
Burnet Institute, Melbourne, Australia
4 shared publicationsDebra Ten Brink
Burnet Institute, Melbourne, Australia
3 shared publications- Karly I. Cini
Global Adolescent Health Group Maternal Child and Adolescent Health Program Burnet Institute Melbourne Australia
3 shared publications Kelvin Burke
Burnet Institute Melbourne Victoria Australia
2 shared publications- Peter Azzopardi
Burnet Institute
2 shared publications - Phone Myint Win
Burnet Institute Myanmar, Yangon, Myanmar
2 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by Springer Nature in BMC Global and Public Health
- Vol. 4 (1) , 78
Estimating the impact and cost-effectiveness of antenatal care approaches in 24 low- and middle-income countries: a modelling study
- 12 August 2026
- Published by Springer Nature in BMC Global and Public Health
- Vol. 4 (1) , 78
Open AccessEstimating the impact and cost-effectiveness of antenatal care approaches in 24 low- and middle-income countries: a modelling study
- Open Access
- 25 July 2026
- Published by Wiley in Journal of the International AIDS Society
- Vol. 29 (S3) , e70171
Optimizing HIV Spending Among Key Populations in Five Latin American and Caribbean Countries: A Mathematical Modelling Study
Introduction: From 2010 to 2024, the Latin America region experienced a 13% increase in new HIV acquisitions, while progress in reducing HIV acquisitions has slowed in the Caribbean. We conducted allocative efficiency studies for five countries in the Latin America and Caribbean region, aiming to estimate how HIV spending could be optimally allocated for maximal impact. Methods: Between 2021 and 2025, we collaborated with national partners in Colombia, Costa Rica, Dominican Republic, El Salvador and Honduras to develop national Optima HIV models incorporating country‐specific key populations. Prevention, testing and antiretroviral therapy (ART) interventions were parameterized using country‐specific unit costs, coverage estimates and effectiveness values. For each country, we projected HIV incidence, mortality and treatment resource needs from 2025 to 2030 for multiple scenarios: fixed intervention coverage (status quo), fixed spending allocations (counterfactual), and most recent spending optimized across interventions to minimize cumulative HIV acquisitions and HIV‐related deaths. Results: With the status quo continued, HIV incidence was projected to decline by 2030 in two countries, stabilize in two and increase in one country. Transgender women and men who have sex with men have the highest incidence rate. Due to ongoing increases in the number of diagnosed people living with HIV, by 2030, annual ART resources will need to increase by 1%–15% to maintain the existing treatment coverage. Compared with the counterfactual (fixed spending) scenario, optimization of existing resources could avert 18%–33% of new HIV acquisitions and 5%–31% of HIV‐related deaths over 2025–2030 by prioritizing primarily ART. If modelled ART unit costs reduce by 25%, then 23%–69% of projected HIV acquisitions and 8%–61% of HIV‐related deaths could be averted by reinvesting savings to scale‐up interventions for country‐specific key populations instead of lower‐yield interventions such as untargeted HIV testing. Conclusions: This multi‐country modelling study demonstrates the potential to reduce new HIV acquisitions and HIV‐related deaths across Latin America and the Caribbean without increasing total spending. Recent reductions in treatment costs provide greater flexibility to invest in key population‐focused services which could amplify epidemic impact. The findings underscore the importance of aligning HIV resources with epidemic drivers and expanding targeted prevention for key populations.
- 25 July 2026
- Published by Wiley in Journal of the International AIDS Society
- Vol. 29 (S3) , e70171
Open AccessOptimizing HIV Spending Among Key Populations in Five Latin American and Caribbean Countries: A Mathematical Modelling Study
Introduction: From 2010 to 2024, the Latin America region experienced a 13% increase in new HIV acquisitions, while progress in reducing HIV acquisitions has slowed in the Caribbean. We conducted allocative efficiency studies for five countries in the Latin America and Caribbean region, aiming to estimate how HIV spending could be optimally allocated for maximal impact. Methods: Between 2021 and 2025, we collaborated with national partners in Colombia, Costa Rica, Dominican Republic, El Salvador and Honduras to develop national Optima HIV models incorporating country‐specific key populations. Prevention, testing and antiretroviral therapy (ART) interventions were parameterized using country‐specific unit costs, coverage estimates and effectiveness values. For each country, we projected HIV incidence, mortality and treatment resource needs from 2025 to 2030 for multiple scenarios: fixed intervention coverage (status quo), fixed spending allocations (counterfactual), and most recent spending optimized across interventions to minimize cumulative HIV acquisitions and HIV‐related deaths. Results: With the status quo continued, HIV incidence was projected to decline by 2030 in two countries, stabilize in two and increase in one country. Transgender women and men who have sex with men have the highest incidence rate. Due to ongoing increases in the number of diagnosed people living with HIV, by 2030, annual ART resources will need to increase by 1%–15% to maintain the existing treatment coverage. Compared with the counterfactual (fixed spending) scenario, optimization of existing resources could avert 18%–33% of new HIV acquisitions and 5%–31% of HIV‐related deaths over 2025–2030 by prioritizing primarily ART. If modelled ART unit costs reduce by 25%, then 23%–69% of projected HIV acquisitions and 8%–61% of HIV‐related deaths could be averted by reinvesting savings to scale‐up interventions for country‐specific key populations instead of lower‐yield interventions such as untargeted HIV testing. Conclusions: This multi‐country modelling study demonstrates the potential to reduce new HIV acquisitions and HIV‐related deaths across Latin America and the Caribbean without increasing total spending. Recent reductions in treatment costs provide greater flexibility to invest in key population‐focused services which could amplify epidemic impact. The findings underscore the importance of aligning HIV resources with epidemic drivers and expanding targeted prevention for key populations.
- Open Access
- 1 October 2025
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 42, 100676
Establishing HIV transmission pathways in Bhutan: a modelling study
- 1 October 2025
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 42, 100676
Open AccessEstablishing HIV transmission pathways in Bhutan: a modelling study
- Open Access
- 11 July 2025
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 5 (7) , e0004548
Optimising TB investments in Belarus, Moldova, Kyrgyz Republic, Tajikistan and Uzbekistan: An allocative efficiency analysis
High rates of drug-resistant tuberculosis (TB) are a barrier to achieving End TB-strategy targets in Eastern Europe and Central Asia. This analysis collates results from five country-level modelling studies to identify priorities to reduce TB burden. Allocative efficiency studies were conducted in 2023 in Belarus, Kyrgyz Republic, Moldova, Tajikistan and Uzbekistan using the Optima TB model to determine the optimised distribution of funds to maximise health outcomes with given resources. A baseline scenario of continued 2022 spending was compared to scenarios with spending optimised across prevention, screening and treatment interventions to reduce TB incidence and deaths over 2024–2030. Modelled pulmonary TB incidence ranged from 25-119 per 100,000 population, and 14 − 43% of new/relapse TB cases were drug resistant. In all countries, optimizing current spending involved: expanding shorter treatment regimens (6–9 months) for drug-resistant-TB over standard regimens (18–20 months); reducing mass screening and mandatory testing and expanding community-based active case finding focused among populations at higher TB risk; and scaling-up TB preventive treatment. It was recommended to expand contact tracing in three countries and to improve cost-effectiveness in two countries by focusing on child household contacts first. With current spending optimised, pulmonary TB incidence was projected to decrease to 19 − 95 per 100,000 population by 2030, averting 1 − 13% of new/relapse TB cases and 1 − 18% of TB-related deaths from 2024-2030 compared to continued baseline spending. In three countries, optimised allocation of 150% of current spending had minimal additional epidemic impact. There are opportunities to reallocate TB funds more cost-effectively in Eastern Europe and Central Asia, but End TB targets may remain out of reach without new and prospective interventions.
- 11 July 2025
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 5 (7) , e0004548
Open AccessOptimising TB investments in Belarus, Moldova, Kyrgyz Republic, Tajikistan and Uzbekistan: An allocative efficiency analysis
High rates of drug-resistant tuberculosis (TB) are a barrier to achieving End TB-strategy targets in Eastern Europe and Central Asia. This analysis collates results from five country-level modelling studies to identify priorities to reduce TB burden. Allocative efficiency studies were conducted in 2023 in Belarus, Kyrgyz Republic, Moldova, Tajikistan and Uzbekistan using the Optima TB model to determine the optimised distribution of funds to maximise health outcomes with given resources. A baseline scenario of continued 2022 spending was compared to scenarios with spending optimised across prevention, screening and treatment interventions to reduce TB incidence and deaths over 2024–2030. Modelled pulmonary TB incidence ranged from 25-119 per 100,000 population, and 14 − 43% of new/relapse TB cases were drug resistant. In all countries, optimizing current spending involved: expanding shorter treatment regimens (6–9 months) for drug-resistant-TB over standard regimens (18–20 months); reducing mass screening and mandatory testing and expanding community-based active case finding focused among populations at higher TB risk; and scaling-up TB preventive treatment. It was recommended to expand contact tracing in three countries and to improve cost-effectiveness in two countries by focusing on child household contacts first. With current spending optimised, pulmonary TB incidence was projected to decrease to 19 − 95 per 100,000 population by 2030, averting 1 − 13% of new/relapse TB cases and 1 − 18% of TB-related deaths from 2024-2030 compared to continued baseline spending. In three countries, optimised allocation of 150% of current spending had minimal additional epidemic impact. There are opportunities to reallocate TB funds more cost-effectively in Eastern Europe and Central Asia, but End TB targets may remain out of reach without new and prospective interventions.
- Open Access
- 6 April 2023
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 13, 100187
Foregone health care in adolescents from school and community settings in Indonesia: a cross-sectional study
- 6 April 2023
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 13, 100187
Open AccessForegone health care in adolescents from school and community settings in Indonesia: a cross-sectional study
- Open Access
- 1 July 2021
- Published by Elsevier in Asian Journal of Psychiatry
- Vol. 61, 102650
Mental health of adolescents in Myanmar: A systematic review of prevalence, determinants and interventions
- 1 July 2021
- Published by Elsevier in Asian Journal of Psychiatry
- Vol. 61, 102650
Open AccessMental health of adolescents in Myanmar: A systematic review of prevalence, determinants and interventions
- Open Access
- 15 January 2021
- Published by Taylor & Francis in Global Health Action
- Vol. 14 (1) , 1844976
Matching action to need: an analysis of Global Burden of Disease 2017 and population health data to focus adolescent health policy and actions in Myanmar
Background: Myanmar is a country undergoing rapid transitions in health. Its national strategic policy for young people’s health is being revised but there is a paucity of population data to inform local priorities and needs. Objective: In this paper we describe a comprehensive profile of adolescent health in Myanmar to focus policy and health actions. Methods: We used available primary data, and modelled estimates from the GBD 2017, to describe health outcomes (mortality and morbidity), health risks and determinants for adolescents in Myanmar between 1990–2017. A governance group of key stakeholders guided the framing of the study, interpretation of findings, and recommendations. Results: Overall health has improved for adolescents in Myanmar since 1990, however adolescent mortality remains high, particularly so for older adolescent males; all-cause mortality rate for 10–24 years was 70 per 100,000 for females and 149 per 100,000 for males (16,095 adolescent deaths in 2017). Overall, the dominant health problems were injuries for males and non-communicable disease for females in a context of ongoing burden of communicable and nutritional diseases for both sexes, and reproductive health needs for females. Health risks relating to undernutrition (thinness and anaemia) remain prevalent, with other health risks (overweight, binge alcohol use, and substance use) relatively low by global and regional standards but increasing. Gains have been made in social determinants such as adolescent fertility and modern contraception use; however, advances have been more limited in secondary education completion and engagement in employment and post education training. Conclusions: These results highlight the need to focus current efforts on addressing disease and mortality experienced by adolescents in Myanmar, with a specific focus on injury, mental health and non-communicable disease.
- 15 January 2021
- Published by Taylor & Francis in Global Health Action
- Vol. 14 (1) , 1844976
Open AccessMatching action to need: an analysis of Global Burden of Disease 2017 and population health data to focus adolescent health policy and actions in Myanmar
Background: Myanmar is a country undergoing rapid transitions in health. Its national strategic policy for young people’s health is being revised but there is a paucity of population data to inform local priorities and needs. Objective: In this paper we describe a comprehensive profile of adolescent health in Myanmar to focus policy and health actions. Methods: We used available primary data, and modelled estimates from the GBD 2017, to describe health outcomes (mortality and morbidity), health risks and determinants for adolescents in Myanmar between 1990–2017. A governance group of key stakeholders guided the framing of the study, interpretation of findings, and recommendations. Results: Overall health has improved for adolescents in Myanmar since 1990, however adolescent mortality remains high, particularly so for older adolescent males; all-cause mortality rate for 10–24 years was 70 per 100,000 for females and 149 per 100,000 for males (16,095 adolescent deaths in 2017). Overall, the dominant health problems were injuries for males and non-communicable disease for females in a context of ongoing burden of communicable and nutritional diseases for both sexes, and reproductive health needs for females. Health risks relating to undernutrition (thinness and anaemia) remain prevalent, with other health risks (overweight, binge alcohol use, and substance use) relatively low by global and regional standards but increasing. Gains have been made in social determinants such as adolescent fertility and modern contraception use; however, advances have been more limited in secondary education completion and engagement in employment and post education training. Conclusions: These results highlight the need to focus current efforts on addressing disease and mortality experienced by adolescents in Myanmar, with a specific focus on injury, mental health and non-communicable disease.